The objectives of this study are to characterise immune responses in people with CoV-SARS-2 infection and use this knowledge to advance vaccine design, treatment options, and diagnostic reagents. Eligible participants will include people diagnosed with SARS-CoV-2 infection, and may include recently returned travellers and non-travellers in the community presenting to tertiary hospital healthcare facilities. Recruitment will be opportunistic, and sampling intensity may vary depending on the phase of the outbreak. Participants can be enrolled at any timepoint (up to 6 months) following diagnosis of SARS-CoV-2 infection (COVID-19). Blood samples and clinical data will be collected.

Inclusion Criteria:

• Main cohort

  1. Diagnosed with CoV-SARS-2 infection
  2. 16 years of age or older
  3. Have provided informed consent Paediatric cohort

  1. Diagnosed with CoV-SARS-2 infection

  2. Less than 16 years of age

  3. Informed consent provided by parent or caregiver

     Exclusion Criteria:

     Main cohort

  1. 15 years of age or younger
  2. Inability or unwillingness to provide informed consent or abide by the requirements of the study Paediatric cohort
  1. 16 years of age or older
  2. Inability or unwillingness of parent or caregiver to provide informed consent or abide by the requirements of the study -

Participants will be adults, adolescents or children diagnosed with COVID-19 and attending a major teaching hospital located in Sydney, New South Wales Australia.

Access to samples and data is governed by the Protocol Steering Committee. Requests can be made to the Committee (via the Principal Investigators).